Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

499.49 -9.26 (-1.82%)

Delayed Quote Updated: 3:17 PM EDT, Oct 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

77 78 Next >

Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress

June 14, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Should Quality-Oriented Investors Explore VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX)? ↗

June 12, 2024

Why NASDAQ:VRTX Stands Out as a Quality Stock.

Via Chartmill

2 Healthcare Stocks to Buy Hand Over Fist in June ↗

June 12, 2024

They both have pretty impressive pasts, and their prospects look just as bright.

Via The Motley Fool

Alphabet To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

June 11, 2024

Via Benzinga

$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today ↗

June 05, 2024

Via Benzinga

This Is What Whales Are Betting On Vertex Pharmaceuticals ↗

June 03, 2024

Via Benzinga

Analyst Expectations For Vertex Pharmaceuticals's Future ↗

May 31, 2024

Via Benzinga

Healthcare And Biotech Investing: Breakthroughs In The Treatment Of Cancer At ASCO ↗

June 10, 2024

Healthcare stocks underperformed YTD because of weakness in UNH and strength in Technology and Communication Services.

Via Talk Markets

Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought ↗

June 09, 2024

These companies could generate explosive growth over time.

Via The Motley Fool

Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst ↗

June 07, 2024

Arcturus Therapeutics shared Phase 1 and Phase 1b trial results for ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis, showing FEV1 improvements and safety .

Via Benzinga

Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®

June 07, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

While growth is established for NASDAQ:VRTX, the stock's valuation remains reasonable. ↗

May 29, 2024

NASDAQ:VRTX is showing decent growth, but is still valued reasonably.

Via Chartmill

2 Biotech Stocks to Buy in May ↗

May 25, 2024

You could buy these in any month, really.

Via The Motley Fool

Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity ↗

May 23, 2024

Via Benzinga

Large Cap BIopharmaceuticals Overview ↗

June 03, 2024

As a defensive play healthcare is weighted at about 12% of the S&P 500.

Via Talk Markets

Topics Stocks

3 No-Brainer Stocks to Buy in June ↗

June 02, 2024

Now is the time to invest in these great stocks.

Via The Motley Fool

5 Top Stocks to Buy in June ↗

June 02, 2024

This medley of growth, value, and income stocks is poised to thrive long-term, even if the stock market sells off this summer.

Via The Motley Fool

S&P 500 Giants Lead Five Healthy Stocks Near Buy Points ↗

June 01, 2024

Eli Lilly is in a buy zone, while rival Novo Nordisk forged a lower entry.

Via Investor's Business Daily

Topics Stocks

A Very Bullish Reversal Produces A Huge Batch Of Actionable Stocks ↗

May 31, 2024

It is very hard to get excited about what I'm seeing in the stock market because things have not been the way I've wanted them to be. In this video, I want to show you something as we look at a monthly...

Via Talk Markets

Should you consider NASDAQ:VRTX for quality investing? ↗

May 22, 2024

VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) Exhibits Quality Stock Traits. Here's Why.

Via Chartmill

Vertex Stock Recently Hit All-Time High, Leads 8 Top Performers New To IBD Stock Lists ↗

May 31, 2024

Vertex stock was one of a select group of eight that made it onto IBD top-stocks lists Friday. The big pharma is near its all-time high.

Via Investor's Business Daily

Should Abbott and DexCom Investors Be Worried About Vertex Pharmaceuticals? ↗

May 30, 2024

Vertex might not present a clear and present danger to Abbott and DexCom but could present a clear future threat.

Via The Motley Fool

Arcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously Optimistic ↗

May 28, 2024

Arcturus Therapeutics' early Phase 1 results show ARCT-032 is safe and well-tolerated, with promising improvements in lung function.

Via Benzinga

Got $500? 3 Pharma Stocks to Buy and Hold Forever ↗

May 26, 2024

These players might even beat the market when the conditions are right.

Via The Motley Fool

Is It Too Late to Buy Vertex Pharmaceuticals Stock? ↗

May 26, 2024

Shares of the growing biotech company have doubled in three years.

Via The Motley Fool

3 High-Flying Stocks That Could Soar Even More ↗

May 25, 2024

The momentum should continue for Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals.

Via The Motley Fool

SLB, First Solar And 2 Other Stocks Insiders Are Selling ↗

May 23, 2024

Via Benzinga

Walmart, Vertex Pharmaceuticals And More On CNBC's 'Final Trades' ↗

May 23, 2024

Walmart Inc. reported a "really strong" quarter, with e-commerce sales surging 21%. Adjusted EPS was 60 cents.

Via Benzinga

The 2030 Millionaire’s Club: 3 Biotech Stocks to Buy Now ↗

May 23, 2024

With interest cuts on the horizon, it's a prime time to consider these high-risk-high-reward biotech stocks to buy.

Via InvestorPlace

Vertex to Participate in Upcoming June Investor Conferences

May 22, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

77 78 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.